Spots Global Cancer Trial Database for rovalpituzumab tesirine
Every month we try and update this database with for rovalpituzumab tesirine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Long-Term Study of Rovalpituzumab Tesirine | NCT03543358 | Cancer | rovalpituzumab ... rovalpituzumab ... | 18 Years - | AbbVie | |
| A Long-Term Study of Rovalpituzumab Tesirine | NCT03543358 | Cancer | rovalpituzumab ... rovalpituzumab ... | 18 Years - | AbbVie | |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | NCT02709889 | Malignant Melan... Medullary Thyro... Glioblastoma Large-Cell Neur... Neuroendocrine ... High Grade Gast... Other Neuroendo... Other Solid Tum... | Rovalpituzumab ... Dexamethasone | 18 Years - 99 Years | AbbVie | |
| A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | NCT03026166 | Small Cell Lung... | Ipilimumab Nivolumab Rovalpituzumab ... | 18 Years - | AbbVie | |
| Expanded Access to Rovalpituzumab Tesirine | NCT03503890 | Small Cell Lung... | rovalpituzumab ... | 18 Years - 99 Years | AbbVie | |
| Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) | NCT03061812 | Small Cell Lung... | Rovalpituzumab ... Topotecan Dexamethasone | 18 Years - | AbbVie | |
| A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) | NCT03033511 | Small Cell Lung... | Placebo for dex... Placebo for rov... Rovalpituzumab ... Dexamethasone | 18 Years - | AbbVie | |
| A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer | NCT02874664 | Small Cell Lung... | Rovalpituzumab ... | 18 Years - | Stemcentrx | |
| A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer | NCT02819999 | Small Cell Lung... | Rovalpituzumab ... Cisplatin Etoposide | 18 Years - | AbbVie | |
| Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT03334487 | Small Cell Lung... | Dexamethasone Rovalpituzumab ... | 18 Years - | AbbVie | |
| Expanded Access to Rovalpituzumab Tesirine | NCT03503890 | Small Cell Lung... | rovalpituzumab ... | 18 Years - 99 Years | AbbVie | |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | NCT02709889 | Malignant Melan... Medullary Thyro... Glioblastoma Large-Cell Neur... Neuroendocrine ... High Grade Gast... Other Neuroendo... Other Solid Tum... | Rovalpituzumab ... Dexamethasone | 18 Years - 99 Years | AbbVie | |
| A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) | NCT03033511 | Small Cell Lung... | Placebo for dex... Placebo for rov... Rovalpituzumab ... Dexamethasone | 18 Years - | AbbVie | |
| Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer | NCT02674568 | Small Cell Lung... | Rovalpituzumab ... | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
